Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Breast Cancer

Breast cancer is the most common non-skin cancer among women. The chance of developing invasive breast cancer at some point in a women's life is about 1 in 8 or 13% of women. It is estimated that in 2007 about 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  HireLifeScience.com, the premier career networking website for ... th annual career fair at The NJ ... Edison, NJ on September ... Actavis and AstraZeneca.  Additional Pharmaceutical, Biotechnology and Medical ... & Johnson, MedImmune, DSM Nutritional Products, LifeCell, Duke ...
(Date:6/3/2015)... 2015 The National Center for ... record by scaling CD-adapco’s flagship simulation tool STAR-CCM+® ... , STAR-CCM+ is a comprehensive multidisciplinary engineering ... innovation and lower product development costs. CD-adapco joined ... manufacturer Cray to push the code to new ...
(Date:6/3/2015)... 03, 2015 From smart street lighting ... part in enabling success in dealing with important Societal ... leaders helped bring focus to the role and further ... Photonics21 annual meeting last week in Brussels. ... held 28 and 29 May at the Hotel Le ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced the ... , Test, Application & End User - Forecast to ... bioburden testing market is expected to reach $565.6 Million ... a CAGR of 9.8% from 2014 to 2019 ... market is segmented into consumables and instruments. The consumables ...
Breaking Biology Technology:AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... a private,biotechnology company and leading developer of clean ... Singapore,Pte. Ltd. (CLS). CLS is the company,s first ... the company,s research and development operations in the,U.S. ... business in,both the innovator and generics markets. ...
... Inc. (Amex: PLX ), announced today the pricing ... common stock at a,public offering price of $5.00 per ... underwriters to purchase up to 1,500,000 additional shares of,common ... Bank is acting as sole book-running manager for this,offering. ...
... Inc. (Nasdaq: HGSI ) today announced that it ... for the quarter ended,September 30, 2007. These results are ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) The conference call will ... Thursday, November 1, 2007, at 11:00 am Eastern Time. ...
Cached Biology Technology:Codexis Opens Singapore Laboratory 2Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... at the IRCM in Montral found a possible alternative ... the IRCM,s President and Scientific Director, the team discovered ... could be targeted to develop a new approach that ... as chemotherapy and radiation therapy. The study,s results are ...
... created a new method to generate bone cells which could ... fractures or those who need hip replacement surgery due to ... Emmajayne Kingham at the University of Southampton in collaboration with ... Small , cultured human embryonic stem cells on to the ...
... for Valentine,s Day, the American Chemical Society (ACS), the world,s ... video today featuring five chemistry facts that highlight why chocolate, ... by the ACS Office of Public Affairs, is available at ... of chocolate contains hundreds of compounds, many with beneficial properties. ...
Cached Biology News:Researchers discover 'Achilles' heel' for lymphoid leukemia 2Stem cell breakthrough could lead to new bone repair therapies on nanoscale surfaces 2